When to stop Acitrom (Ximelagatran) before surgery and when to use bridging therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Perioperative Management of Acitrom (Vitamin K Antagonist) Before Surgery

Acitrom (a vitamin K antagonist similar to warfarin) should be stopped approximately 5 days before surgery and resumed 12-24 hours after surgery when adequate hemostasis is achieved. 1

Preoperative Management

Timing of Discontinuation

  • Stop Acitrom approximately 5 days before surgery to allow INR to normalize 1
  • The exact timing depends on the patient's current INR and the target INR for the procedure 1
  • For minor dental procedures, dermatologic procedures, or cataract surgery, consider continuing Acitrom with local hemostatic measures instead of stopping 1

Bridging Therapy Recommendations

  • For patients with high thromboembolism risk (mechanical heart valve, atrial fibrillation with high CHADS2 score, recent VTE), use bridging anticoagulation during Acitrom interruption 1
  • For patients with low thromboembolism risk, no bridging is recommended 1
  • When bridging is needed, use therapeutic-dose LMWH with the last dose administered approximately 24 hours before surgery 1

Risk Stratification for Bridging Decisions

High Thromboembolism Risk (Bridging Recommended)

  • Mechanical heart valve (mitral position, older aortic valve, or stroke/TIA within 6 months) 1
  • Atrial fibrillation with CHADS2 score ≥5 or recent stroke/TIA within 3 months 1
  • Recent VTE within 3 months or severe thrombophilia 1

Low Thromboembolism Risk (No Bridging Needed)

  • Bileaflet aortic valve without risk factors 1
  • Atrial fibrillation with CHADS2 score ≤2 without prior stroke/TIA 1
  • VTE >12 months ago with no other risk factors 1

Surgery-Specific Considerations

High Bleeding Risk Procedures

  • For high bleeding risk procedures (neurosurgery, major surgery >45 minutes), ensure complete normalization of INR 1
  • If bridging with LMWH is used, resume therapeutic-dose LMWH 48-72 hours after surgery rather than within 24 hours 1

Low-to-Moderate Bleeding Risk Procedures

  • For procedures with lower bleeding risk, consider shorter interruption periods 1
  • For minimal bleeding risk procedures (minor dermatologic, dental, or cataract procedures), consider continuing Acitrom with local hemostatic measures 1

Postoperative Management

Resuming Acitrom

  • Resume Acitrom 12-24 hours after surgery (evening of or next morning) when adequate hemostasis is achieved 1
  • Initial dose can be the patient's usual maintenance dose 1
  • If bridging is used, continue LMWH until the INR returns to the therapeutic range 1

Monitoring After Resumption

  • Check INR 5-7 days after resuming Acitrom to ensure therapeutic levels 1
  • Monitor for signs of bleeding or thromboembolism during the transition period 1

Special Considerations

  • For patients with coronary stents, defer elective surgery for at least 6 weeks after bare-metal stent placement and 6 months after drug-eluting stent placement 1
  • For urgent surgery in patients on Acitrom, consider prothrombin complex concentrate rather than fresh frozen plasma for rapid reversal 2
  • The risk of surgical bleeding if anticoagulants are continued is often lower than the risk of thrombosis if they are withdrawn inappropriately 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.